Use of insulin sensitizers in NASH.
This article briefly discusses nonalcoholic fatty liver disease (NAFLD) and its association with the metabolic syndrome, its pathogenesis and natural history. It then presents a detailed discussion on the efficacy and safety of different insulin sensitizers in patients who have NASH.
Khashab
Mouen
M
Division of Gastroenterology and Hepatology, Indiana University School of Medicine, WD OPW 2005, 1001 West 10th Street, Indianapolis, IN 46202, USA.
Chalasani
Naga
N
D000410:Alanine Transaminase / Q000097:blood; D002839:Chromans / Q000627:therapeutic use; D005234:Fatty Liver / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000150:complications; D008687:Metformin / Q000627:therapeutic use; D000077205:Pioglitazone; D011379:Prognosis; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use; D000077288:Troglitazone
D002839:Chromans; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008687:Metformin; D000410:Alanine Transaminase; D000077288:Troglitazone; D000077205:Pioglitazone